AbstractIn the past, efforts have been made to find a cure for diabetes, mainly evaluating new classes of compounds to explore their potency. In this study, we present the synthesis and evaluation of carbonylbis(hydrazine‐1‐carbothioamide) derivatives as potential α‐glucosidase inhibitors, employing both in vivo and in silico investigations. The in vitro experiments revealed that all tested compounds were significantly potent for α‐glucosidase inhibition, with the lead compound 3a displaying approximately 80 times higher activity than acarbose. To delve deeper, in silico induced fit docking, pharmacokinetics, and molecular dynamics studies were conducted. Significantly, compound 3a exhibited a docking score of −7.87 kcal/mol, surpassing acarbose, which had a docking score of −6.59 kcal/mol. The in silico ADMET indicated that most of the synthesized compounds have properties conducive to drug development. Molecular dynamics analysis demonstrated that, when the ligand 3a was coupled with the target 3TOP, Cα‐RMSD backbone RMSD values below 2.4 Å and “Lig_fit_Prot” values below 2.7 Å were observed. QSAR analysis demonstrates that the “fOC8A” descriptor positively correlates with α‐glucosidase inhibition activity, while “lipoplus_AbSA” positively contributes and “notringC_notringO_8B” negatively contributes to this activity.